|
Cardiovascular Monitoring Company InteloMed, Inc. to Present at Board of ... - SYS-CON Media (press release) |
 |
 |
  
WEXFORD, PA -- (Marketwired) -- 08/13/15 -- InteloMed, Inc., an emerging leader and developer of hardware and software for non-invasive cardiovascular monitoring, will present at the Board of Nephrology Examiners Nursing and Technology ("BONENT") Northeast Regional Seminar in Newark, New Jersey on August 16. BONENT is a leading professional education and credentialing organization in nephrology with membership of over 7,000 nurses and technicians.
Lori Poole, RN, MSN and Helene Colaizzi, DPM of InteloMed, will present on the Company's lead product CVInsight?, a non-invasive, easy-to-use platform for monitoring patient cardiovascular stress during hemodialysis treatment and informing clinical decisions.
"BONENT is committed to improving care for nephrology patients globally," commented RJ Picciano BA, CHT, OCDT, CHBT, BONENT's President. She is also the Fluid Volume Educator at the Centers for Dialysis Care in Cleveland, OH, where the CVInsight? Platform is currently used. "It is important that we educate our members about new advances in monitoring cardiovascular response during hemodialysis in order to increase patient safety and treatment efficacy."
"Cardiovascular events during hemodialysis treatments are common and can be deleterious to the patient and costly to the health care system," stated Jill Schiaparelli, InteloMed President and CEO. "We're very pleased to have this opportunity to share the benefits of the CVInsight? Platform with the BONENT membership."
About BONENT
The Board of Nephrology Examiners Nursing Technology ("BONENT") is a non-profit organization promoting excellence in the quality of care of nephrology patients in the United States and many countries around the world. BONENT serves as a trusted representative voice to policy makers by urging legislative and regulatory movement toward meaningful training, certification and credentialing of nephrology practitioners. Recognized since 1974 as the leading, independent professional certification body, BONENT identifies safe and competent practitioners in nephrology by providing highly regarded, comprehensive specialty examinations and credentialing.
For more information about BONENT, visit www.Bonent.org.
About InteloMed
InteloMed is redefining the standard of care in intelligent cardiovascular monitoring in hospitals and health care facilities through its non-invasive CVInsight? Platform. The CVInsight? Platform provides real-time insights on the stress level of the cardiovascular system to inform clinical decisions which, as part of a well-managed care plan, may lead to earlier detection of cardiovascular decline, earlier intervention, decreased hospitalization and improved patient outcomes. The CVInsight? Platform has functionality in hospital and outpatient settings and has clinical applications in multiple areas including hemodialysis, heart failure, and the surgical continuum.
For more information, visit www.InteloMed.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.
CONTACT
PR / Media Contact:
Matthew Bird
President
1-800-PublicRelations, Inc.
646.401.4499
[email protected]
|
|
Few Referrals for Transplant Evaluation Among Dialysis Patients - Renal and Urology News |
|
|
August 13, 2015
Findings among end-stage renal disease patients initiating dialysis in Georgia.
(HealthDay News) -- Few new end-stage renal disease (ESRD) patients are referred for kidney transplant evaluation within one year of starting treatment, although referral practices vary considerably, according to a study published in the Journal of the American Medical Association.
Rachel E. Patzer, Ph.D., M.P.H., from the Emory University School of Medicine in Atlanta, and colleagues assessed variation in dialysis facility referral for kidney transplant evaluation among 308 Georgia dialysis facilities (15,279 incident, adult patients with ESRD) from January 2005 to September 2011, with follow up through September 2012. Referral data were linked to transplant center data.
The researchers found that the median within-facility percentage of patients referred within one year of starting dialysis was 24.4%, and varied from 0 to 75%. Compared with facilities in the highest tertile of referral (>31.3%), facilities in the lowest tertile of referral (<19.2%) were more likely to treat patients living in high-poverty neighborhoods, had a higher patient-to-social worker ratio, and were more likely nonprofit.
"Variables associated with referral were not always associated with waitlisting, suggesting that different factors may account for disparities in referral," the authors write.
One author disclosed financial ties to a dialysis center.
Sources
- Patzer, RE; Plantinga, LC; Paul, S; et al. JAMA 2015;314(6):582-594; doi:10.1001/jama.2015.8897.
- Kucirka, LM; Purnell, TS; and Segev, DL. JAMA 2015;314(6):565-567; doi:10.1001/jama.2015.8932.
|
|
|
Coaching and Financial Incentives May Reduce Phosphorus - Renal and Urology News |
|
|
August 13, 2015
Patients with hyperphosphatemia lowered their phosphorus levels with a dietitian's guidance or cash incentive.
Employing novel health strategies, along with phosphate binder medication, may help hemodialysispatients reduce excess phosphorus, a small pilot study suggests.
Peter R. Reese, MD, of the University of Pennsylvania in Philadelphia and colleagues randomly assigned 36 hemodialysis patients to 3 groups—dietary and medication coaching, financial incentives, or usual care—for 10 weeks. Baseline serum phosphorus levels ranged from 5.6 to 7.6 mg/dl.
According to results published in the Journal of Renal Nutrition, patients' monthly serum phosphorus levels declined in all groups: 0.32 mg/dl for patients receiving a monetary reward, 0.4 in coached patients, and 0.24 in usual care patients.
“These findings suggest that a future trial might combine education (using a coach or a different delivery method) with financial incentives to give patients the knowledge and motivation to change nutritional and medication adherence habits,” the investigators explained.
Understanding and adopting the dietary restrictions necessary to limit phosphorus is challenging for patients, especially when labels fail to note phosphorus amounts. Patients also need to remember to take phosphate binders with every meal and phosphorus-rich snack. The renal dietitian bolstered patients' knowledge about both diet and phosphate binder therapy. Individualized coaching 3 times a week included assessments, goal setting, and practical tips, such as a shopping lists and recipes.
Patients in the financial incentives group received only a cash reward ($1.50 per day) when they lowered their phosphorus levels to a reasonable target of 5.5 mg/dl or below or when their serum phosphorus levels declined by at least 0.5 mg/dl from the prior reading. Successful patients also were entered into a lottery to win $50.
Motivational techniques played a role in both interventions. The dietitian used motivational interviewing to promote readiness for behavior change in patients. Patients in the financial incentives group likewise received messages to reinforce goal attainment and offset inaction.
Larger and longer studies are needed to investigate the magnitude and durability of improvements in phosphorus levels with these interventions, the investigators stated. This study was not powered to detect clinical differences between groups, but it determined the feasibility of using novel strategies and corroborated findings from similar research on phosphorus education. Other studies have shown that self-management and financial interventions improve medication adherence, smoking cessation, substance abuse, glycemic control, and weight loss.
Roughly half of eligible patients in the current study agreed to participate in the program and no one dropped out. All expressed interest in receiving similar support in the future.
Source
- Reese, PP; Mgbako, O; Mussell, A; et al. Journal of Renal Nutrition; doi: 10.1053/j.jrn.2015.06.001.
|
|
Medical Dialysis Devices Market 2015 – Global Industry Trends,Share ... - Medgadget.com (blog) |
|
|
The report – Global Medical Dialysis Devices Industry presents an executive-level overview of the Global Medical Dialysis Devices market. The Global Medical Dialysis Devices market is expected to demonstrate a positive growth trend in the coming years. The market forces that will shape the growth of this market have been scrutinized in detail in this report.
Read Complete Report Visit @ http://www.marketresearchstore.com/report/global-medical-dialysis-devices-industry-research-report-2015-27762
Comprehensive data related to the market trends has been included in this report. The market drivers that will fuel the growth of the market during the forecast period are mentioned in this report. Furthermore, the regulatory environment in the Global Medical Dialysis Devices market and its impact on the Global Medical Dialysis Devices industry performance has been assessed in this report. The restraining factors that will result in decline in popularity of certain product segments have also been covered in this report. The potential opportunities and their impact on the Global Medical Dialysis Devices market is also evaluated in the report.
The key players are expected to tap onto these market opportunities to penetrate the market. Furthermore, the untapped opportunities in emerging economies will provide a considerable impetus to the small, medium, and large companies operating in the Global Medical Dialysis Devices market. These opportunities in turn are projected to have positive impact on the Global Medical Dialysis Devices market. Players in the market are focusing on innovation, which has resulted in a lot of mergers, acquisitions, collaborations, and partnerships. The prominent market players are also focusing to offer a broader range of products. Competitors often are competing on the basis of the cost of the products in the Global Medical Dialysis Devices market.
Request for Sample Report @ http://www.marketresearchstore.com/report/global-medical-dialysis-devices-industry-research-report-2015-27762#requestSample
Around the world, industries are focusing on incorporating green practices in their manufacturing processes. Moreover, products that are manufactured using these green practices or include more eco-friendly ingredients are popular among consumers. This consumer preference will help companies operating in the Global Medical Dialysis Devices market to include greener products and services to their offering.
Contact Us:
Joel John
Deerfield Beach, Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Web: Market Research Store
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
